Filewrapper

USPTO Proposed 2025 Fee Changes Pass the Notice and Comment Period

By Jonathan L. Kennedy

Proposed fee changes for 2025 have passed the notice and comment period and are expected to go into effect in the USPTO’s 2025 fiscal year. The USPTO allowed for public comments on the proposal to be received up until May 28, 2024. The notice of proposed rulemaking followed a public hearing held by the Patent […]

Continue Reading →

Federal Circuit Revives SynQor Patent

By Julie L. Spieker

On February 22, 2021, the United States Court of Appeals for the Federal Circuit reversed the Patent Trial and Appeal Board’s decision that SynQor’s US Patent No. 7,072,190 was unpatentable. SynQor’s ‘190 patent relates to technology that converts DC current from one voltage to another for use in large computer systems and data communication equipment. […]

Continue Reading →

Practitioners Beware: Hidden MPEP Rule Change May Cause Significant Impacts to After Final Practice

By Blog Staff

With the most recent revision to the Manual of Patent Examining Procedure (MPEP) in June 2020, practitioners have noticed a subtle, but potentially significant modification to one of the MPEP sections. The relevant section pertains to a change to the first-action final rejection (FAFR) practice under 706.07(b), ultimately broadening the criteria to issue a FAFR […]

Continue Reading →

“Stairway to Heaven” Holds on to Iconic Riff

One of the most iconic rock songs of the 20th Century came under fire earlier this summer for allegations of copyright infringement. The estate of Randy Wolfe, guitarist for Spirit on the song “Taurus,”brought a copyright suit against Led Zeppelin, frontman Robert Plant, and guitarist Jimmy Page alleging infringement of a guitar riff that opens […]

Continue Reading →

Intellectual Property Protection Options for Software

In a previous blog post, I discussed some of the recent updates issued by the United States Patent and Trademark Office regarding patent eligible subject matter and software patents. As anyone who deals with software patents is aware, there is a lot of uncertainty as to whether software is patent eligible subject matter. While the […]

Continue Reading →

Federal Circuit Weighs in on Abbreviated Biosimilar Applications

The Biologics Price Competition and Innovation Act (BPCIA) establishes an abbreviated pathway for regulatory approval of follow-on biological products that are highly similar to a previously approved product (the reference product).  The general structure of the abbreviated pathway, referred to as “biosimilar” licensure , is similar to that used for Abbreviated New Drug Applications (ANDA) under the […]

Continue Reading →

Stay in Touch

Receive the latest news and updates from us and our attorneys.

Sign Up